+1-888-308-5802      . .

Pharma giant Pfizer to acquire Array BioPharma valued at $11.4 billion

Author : Pankaj Singh | Published Date : 2019-06-19 

Pharma giant Pfizer to acquire Array BioPharma valued at $11.4 billion

Pfizer Inc., the New York-based pharmaceutical multinational, has reportedly announced that it will acquire Array BioPharma Inc., a commercial stage company focused on the discovery, development and commercialization of small molecule medicines to treat cancer and other crucial diseases.

As per trusted sources, Pfizer is paying $48 per share in cash to Array and the total valuation of the deal is estimated at $11.4 billion.

Albert Bourla, CEO, Pfizer was reportedly quoted stating that the merger reinforces the company’s commitment to change the lives of the patients while creating strong shareholder value. The acquisition of Array BioPharma strengthens Pfizer’s biopharmaceutical business and will also enhance the long-term goals of the company while creating an industry leading firm for colorectal cancer along with focusing on the current expertise in prostate and breast cancer, he further added.

For the record, Array’s portfolio includes the approved combined use of MEKTOVI (binimetinib) and BRAFTOVI (encorafenib) for the treatment of BRAF V600E or BRAF V600K mutant unresectable or metastatic melanoma. The combination of these drugs has a significant potential for long term expansion into areas of undiscovered treatment for crucial diseases. These are being investigated in over 30 clinical laboratories across solid tumor indications which include the Phase 3 BEACON trial in BRAF mutant metastatic colorectal cancer (MCRC).

In 2018, 140,250 patients were diagnosed with colon or rectum cancer in the U.S., making it the third most common type of cancer in the country. BRAF mutations apparently occur in more than 15% of colorectal cancer and approximately 50,000 of the diagnosed patients die every year.

Ron Squarer, CEO, Array, reportedly stated that the merger of the companies will bring about great discoveries in the biopharma field and extend the lives of the patients. Array will gain access to a broader research platform and world-class resources by way of its merger with Pfizer which would help the company to continue developing even more options for individuals with unmet needs, Squarer added.

Reportedly, Pfizer is expected to complete the deal in the second half of 2019.

 

Sources: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma

https://www.moneycontrol.com/news/world/pfizer-makes-10-6-billion-cancer-bet-in-cash-deal-for-array-biopharma-4108861.html

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Bayers new CEO initiates management job cuts to accelerate decision-making

Bayers new CEO initiates management job cuts to accelerate decision-making

Published Date: 2023-09-15         Author: Pankaj Singh

Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Published Date: 2023-09-08         Author: Pankaj Singh

Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>

RBC plans job cuts to take on anticipated economic softening

RBC plans job cuts to take on anticipated economic softening

Published Date: 2023-08-25         Author: Pankaj Singh

The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>

© 2024 Fractovia. All Rights Reserved